Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer

Journal of Cancer

Volumn 7, Issue 9, 2016, Pages 1095-1104

  Mego, M ^a,b   Gao, H ^a   Cohen, E N ^a   Anfossi, S ^a   Giordano, A ^a   Sanda, T ^a   Fouad, T M ^a   De Giorgi, U ^a,c   Giuliano, M ^a,d   Woodward, W A ^a   Alvarez, R H ^a,e   Valero, V ^a   Ueno, N T ^a   Hortobagyi, G N ^a   Cristofanilli, M ^a,f   Reuben, J M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e CANCER TREATMENT CENTERS OF AMERICA   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adaptive immunity; Circulating tumors cells; Inflammatory breast cancer

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CD8+ T LYMPHOCYTE; CIRCULATING TUMOR CELL; CLINICAL OUTCOME; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INFLAMMATORY BREAST CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHENOTYPE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 84983638456     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13098     Document Type: Article

References (70)

1. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis 2005; 22:9-23.
2. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97:966-975.
3. Walshe J, Swain S. Clinical aspects of inflammatory breast cancer. Breast Dis 2005; 22:35-44.
4. Ueno NT, Buzdar AU, Singletary SE et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997; 40:321-329.
5. Masuda H, Brewer TM, Liu DD et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes. Ann Oncol. 2014, 25:384-391.
6. Fouad TM, Kogawa T, Liu DD et al. Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer. Cancer Res 2013, 73 (24 Suppl): Abstract P6-12-02.
7. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003; 8:141-148.
8. Cristofanilli M, Valero V, Buzdar AU et al. Inflammatory breast cancer (IBC) and patterns of recurrence--understanding the biology of a unique disease. Cancer 2007; 110:1436-1444.
9. Robertson FM, Bondy M, Yang W et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010; 60:351-375.
10. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3:453-458.
11. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975; 35:512-516.
12. Wong CW, Lee A, Shientag L et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res. 2001; 61:333-338.
13. Baccelli I, Schneeweiss A, Riethdorf S et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013; 31:539-544.
14. Lucci A, Hall CS, Lodhi AK et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012; 13:688-695.
15. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-791.
16. Mego M, Giordano A, De Giorgi U et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research 2015 (In press).
17. Zhan, M., Zhao, H. & Han, Z. C. Signaling mechanisms of anoikis. Histol. Histopathol. 2004; 19:973-983.
18. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol. 2010; 7:693-701.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
20. Green TL, Cruse JM, Lewis RE, Craft BS. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp Mol Pathol. 2013; 95:174-179.
21. Green TL, Santos MF, Ejaeidi AA, Craft BS, Lewis RE, Cruse JM. Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp Mol Pathol. 2014; 97: 44-48.
22. Gruber I, Landenberger N, Staebler A, Hahn M, Wallwiener D, Fehm T. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Res. 2013; 33:2233-2238.
23. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Handbook, 6th edition. New York, NY: Springer 2002.
24. Dawood S, Merajver SD, Viens P et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22:515-523.
25. Singletary SE, Allred C, Ashley P et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83:803-819.
26. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10:6897-6904.
27. Naing A, Reuben JM, Camacho LH et al. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. J Cancer. 2011; 2:81-89.
28. Reuben JM, Lee BN, Li C et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006; 106:2437-2444.
29. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 2005; 19:1905-1911.
30. Bidard FC, Mathiot C, Delaloge S et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21:729-733.
31. Lang JE, Mosalpuria K, Cristofanilli M et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 2009; 113:501-517.
32. Bidard F, Hajage D, Bachelot T et al. Circulating tumor cells and CYFRA 21-1 as outcome-associated biomarkers in first line metastatic breast cancer: results of the IC 2006-04 study. Ann Oncol 2011; 22 (supplement 2): ii41-ii42.
33. Rack BK, Schindlbeck C, Andergassen U et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial [abstract]. J Clin Oncol 2010; 28 (15 Suppl): a1003.
34. Mego M, De Giorgi U, Hsu L et al. Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol 2009; 20:1824-1828.
35. Muraro E, Comaro E, Talamini R et al. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med. 2015; 13:204.
36. Datta J, Berk E, Xu S et al. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res. 2015, 17:71.
37. De Giorgi U, Rihawi K, Aieta M et al. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. J Geriatr Oncol. 2014; 5:156-163.
38. De Giorgi U, Mego M, Scarpi E et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012; 12:264-269.
39. Fujiwara Y, Misawa T, Shiba H et al. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenocarcinoma. Anticancer Res. 2014; 34:5163-5168.
40. Wei X, Huang F, Wei Y et al. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leuk Res. 2014; 38:694-698.
41. Kobayashi N, Usui S, Kikuchi S et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer. 2012; 75:223-227.
42. Knutson KL, Disis ML, Salazar LG. CD4 regulatory Tcells in human cancer pathogenesis. Cancer Immunol Immunother 2007; 56:271-285.
43. Perez SA1, Karamouzis MV, Skarlos DV et al. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007; 13:2714-2721.
44. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756 -2761.
45. Decker T, Fischer G, Bücke W et al. Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J Cancer Res Clin Oncol. 2012; 138:1945-50.
46. Faghih Z, Erfani N, Haghshenas MR, Safaei A, Talei AR, Ghaderi A. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunology Letters 2014; 158:57-65.
47. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16:3-15.
48. Fehm T, Müller V, Aktas B et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010; 124:403-412.
49. Punnoose EA, Atwal SK, Spoerke JM et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010; 5:e12517.
50. Flores LM, Kindelberger DW, Ligon AH et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010; 102:1495-1502.
51. Sisirak V, Faget J, Vey N et al. Plasmacytoid dendritic cells deficient in IFNa production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology. 2013; 2:e22338.
52. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008; 38:2636-2649.
53. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol. 2004; 172:1380-1390.
54. Vukmanovic-Stejic, M., B. Vyas, P. Gorak-Stolinska, A. Noble, D. M. Kemeny. 2000. Human Tc1 and Tc2/Tc0 CD8 T cell clones display distinct cell surface and functional phenotypes. Blood 2000; 95:231-240.
55. Yen HR, Harris TJ, Wada S et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol. 2009; 183:7161-7168.
56. Hinrichs CS, Kaiser A, Paulos CM et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009; 114:596-599.
57. Faghih Z, Rezaeifard S, Safaei A, Ghaderi A, Erfani N. IL-17 and IL-4 producing CD8+ T cells in tumor draining lymph nodes of breast cancer patients: positive association with tumor progression. Iran J Immunol. 2013; 10:193-204.
58. Zhao Y, Zhao H, Sun Y et al. IL-4 induces a suppressive IL-10-producing CD8+ T cell population via a Cdkn2a-dependent mechanism. J Leukoc Biol. 2013; 94:1103-1112.
59. Noble A, Giorgini A, Leggat JA. Cytokine-induced IL-10-secreting CD8 T cells represent a phenotypically distinct suppressor T-cell lineage. Blood. 2006; 107:4475-4483.
60. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction anmicrometastases in women with breast cancer. Breast Cancer Res Treat. 2005; 91:163-171.
61. Naume B, Gately MK, Desai BB, Sundan A, Espevik T. Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine. 1993; 5:38-46.
62. Brown MA, Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol. 1997; 17:1-32.
63. Swisher SG, Economou JS, Holmes EC, Golub SH. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function. Cell Immunol. 1990; 128:450-461.
64. Yu M, Bardia A, Wittner BS et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339:580-584.
65. Mego M, Mani SA, Lee BN et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer 2012; 130:808-816.
66. Giordano A, Gao H, Anfossi S et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012; 11:2526-2534.
67. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15:195-206.
68. + follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013; 123:2873-2892.
69. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25:1544-1550.
70. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31:860-867.